Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Akorn has announced the receipt of an FDA approvable letter for Akten ophthalmic gel 3.5%, an ocular topical anesthetic drug product.
Subscribe to our email newsletter
The approvable letter identified several minor CMC deficiencies that must be addressed and rectified before final approval is granted. The majority of these items have been addressed in the company’s previous submissions to the FDA. The remaining response will be submitted to the FDA within the next ten days.
Additionally, prior to approval, product labeling must be finalized. The company said that it received proposed labeling from the FDA and will submit final printed labeling within the next ten days.